Shares of Poseida Therapeutics (NASDAQ:PSTX) were jumping 21.2% higher as of 12:08 p.m. EST on Wednesday. The big gain came with the company providing a pipeline update at its virtual R&D Day today.
Poseida said that its virtual R&D Day will include a presentation of a case study for one patient receiving P-PSMA-101. It's an experimental chimeric antigen T cell receptor (CAR-T) therapy that's currently being evaluated in a phase 1 study targeting prostate cancer. The patient in the case study to be discussed experienced a decrease in prostate-specific antigen levels of more than 50% three weeks after receiving P-PSMA-101.
Image source: Getty Images.
For further details see:
Why Poseida Therapeutics Stock Is Popping Today